Demographic, clinical and laboratory SLE characteristics, by country
| Russia (n=232) | Kazakhstan (n=110) | Ukraine (n=94) | |
|---|---|---|---|
| Gender, n (%) | |||
| Male | 14 (6.0%) | 5 (4.5%) | 10 (10.6%) |
| Female | 218 (94.0%) | 105 (95.5%) | 84 (89.4%) |
| Race/ethnicity, n (%) | |||
| Caucasians | 224 (96.6%) | 8 (7.3%) | 94 (100.0%) |
| Asian | 1 (0.4%) | 102 (92.7%) | 0 (0.0%) |
| Black | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Unknown | 7 (3.0%) | 0 (0.0%) | 0 (0.0%) |
| Age at SLE diagnosis, years | |||
| Mean (SD) | 30.3 (12.2) | 31.6 (11.4) | 33.0 (13.3) |
| Median (min–max) | 29.0 (7–68) | 30.5 (12–59) | 32.0 (4–74) |
| Age at the last visit in 2010, years | |||
| Mean (SD) | 36.1 (12.3) | 36.9 (11.4) | 41.7 (21.1) |
| Median (min–max) | 33.0 (18–74) | 36.5 (19–67) | 41 (20–74) |
| SLE duration at the last visit in 2010, years | |||
| Median | 4.5 | 3.0 | 6.8 |
| 25–75% quartile | 0.6–9.1 | 0.0–6.8 | 3.2–12.2 |
| Severe SLE, n (%) | |||
| At the SLE diagnosis | 137/198 (69.2%) | 64/88 (72.7%) | 51/92 (55.4%) |
| At the last visit in 2010 | 108/200 (54.0%) | 69/109 (63.3%) | 53/94 (56.4%) |
| SLE profile at the last visit in 2010 | |||
| Relapsing-remitting | 85 (36.6%) | 39 (35.5%) | 1 (1.1%) |
| Chronic active | 74 (31.9%) | 55 (50.0%) | 90 (95.7%) |
| Unknown, n (%) | 73 (31.5%) | 16 (14.5%) | 3 (3.2%) |
| Laboratory markers of activity (positive test for anti-dsDNA antibodies and/or C3 or C4 below normal ranges) | |||
| At diagnosis | 88/98 (89.8%) | 33/37 (89.2%) | 38/44 (86.4%) |
| At the last visit in 2010 | 143/174 (82.2%) | 54/74 (73.0%) | 52/58 (89.7%) |
| SLE activity by Nasonova, n (%) at the diagnosis | |||
| High | 107/192 (55.7%) | 57/89 (64.0%) | 18/63 (28.6%) |
| Moderate | 71/192 (37.0%) | 29/89 (32.6%) | 19/63 (30.2%) |
| Low | 14/192 (7.3%) | 3/89 (3.4%) | 26/63 (41.3%) |
| SLE activity by Nasonova, n (%) at the last visit in 2010 | |||
| High | 57/201 (28.4%) | 54/110 (49.1%) | 8/93 (8.6%) |
| Moderate | 93/201 (46.3%) | 50/110 (45.5%) | 16/93 (17.2%) |
| Low | 51/201 (25.4%) | 6/110 (5.5%) | 69/93 (74.2%) |
| SELENA-SLEDAI score, mean (SD) | |||
| At SLE diagnosis | 16.6 (10.1) | 18.6 (17.4) | 9.4 (7.8) |
| N | 198 | 89 | 93 |
| At the last visit in 2010 | 13.8 (10.5) | 19.4 (16.9) | 7.2 (6.8) |
| N | 201 | 110 | 94 |
| SDI score, mean (SD) | |||
| At SLE diagnosis | 1.2 (1.9) | 2.0 (2.3) | 1.1 (1.7) |
| N | 198 | 89 | 93 |
| At the last visit in 2010 | 2.0 (2.2) | 3.3 (3.2) | 2.2 (2.0) |
| N | 200 | 109 | 91 |
Percentages were calculated from the valid data.
If SLE profile was impossible to establish retrospectively, it was considered as ‘unknown’.
Patients could have no autoantibody-positive disease at the date of SLE diagnosis but could be autoantibody-positive between the diagnosis and before the last visit in 2010.
SDI, SLE Damage Index; SLE, systemic lupus erythematosus; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index.